England’s Court of Appeal has affirmed a 2012 High Court ruling that pharmaceutical company Genentech’s patent covering human vascular endothelial growth factor (hVEGF) antagonists is valid and has been infringed by Regeneron and Bayer Pharmaceutical’s drug Eylea.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Genentech, hVEGF, Regeneron, Bayer, Trap Eye, patent, Court of Appeal
